🎗Teijin Acquires Exclusive Sales Rights to Transcranial Magnetic Stimulation Device in Japan.
Tokyo, Japan, Oct 16, 2017 — Teijin Pharma Limited Opening a new window, the core company of the Teijin Group’s healthcare business, announced today that it has acquired the exclusive sales rights in Japan to the NeuroStar Transcranial Magnetic Stimulation (TMS) for treating depression that does not respond well to normal antidepressant drug-based therapies.
The NeuroStar TMS device was developed by the U.S. medical device maker Neuronetics, Inc. Opening a new window.Teijin Pharma is now evaluating opportunities to sell this device to medical institutions within the scope of the Japanese national health program.
TEIJIN | News |
https://www.teijin.com/news/2017/ebd171016_22.html